Neostellar Capital Corp. announced its third quarter 2026 financial results with a net asset value of $12.64 per share as of September 30, down from $13.44 in June but up from $9.23 a year earlier. The company expanded its partnership with Magnetar to enhance investment sourcing and due diligence, focusing on AI and data infrastructure firms like OpenAI and Whoop. The Board approved extending the share repurchase program with $25 million remaining, balancing capital deployment between new investments and buybacks. Despite a net loss for the quarter, Neostellar continues to invest in promising private companies and manage its portfolio for long-term value.
Neostellar Capital Corp.'s third quarter 2026 results provide context for financial markets. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 04, 2026 04:02 WIB: Among 142 priced US Financials stocks, 59 rose and 83 fell. Marathon Digital Holdings Inc (MARA) gained 11.20% to USD 7.15 with 100% buy orders and a typical hold time of 24 days. Coinbase Global, Inc. (COIN) rose 5.99% to USD 146.09 but saw 94% sell orders and a hold time of 80 days. Marex Group Limited (MRX) increased 5.19% to USD 68.27 with a typical hold time of 11 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
